New Jersey Center for Cancer Research

Brick, NJ

Not currently accepting

IBI188

A Phase 1b Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS)
Learn more
  • Monoclonal Antibody
  • Phase 1